Bio Pharma Dive
FEBRUARY 18, 2022
According to BioMarin, the regulator has requested additional data to assess the "theoretical" cancer risk to the treatment, information that will take "several quarters" to collect.
World of DTC Marketing
FEBRUARY 17, 2022
The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. The 5-year survival rate has increased by 6% for distant-stage lung cancer, 33% for a regional-stage disease, and 60% for localized disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 18, 2022
The pandemic-induced transition to digital health is, according to the Nuffield Trust, contributing to an “inverse care law” that’s compounding existing health inequalities. But, as demonstrated by initiatives like the Telehealth Equity Coalition (TEC), the sector is taking a united stand against inequitable access. Technological solutions, from online clinics to app-based long-term condition management, have long been hailed as a solution to problems such as limited capacity and low patient aut
Outsourcing Pharma
FEBRUARY 17, 2022
In its forward-looking report on digital health, the consulting outfit offers predictions on what changes are ahead and how they might impact the field.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
FEBRUARY 17, 2022
The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.
World of DTC Marketing
FEBRUARY 18, 2022
Business Insider formed a relationship with eMarketer for so-called “intelligence.” Their report on telehealth has numbers, but that’s not what’s important. We need to understand “why” people are using telehealth and for what purposes versus an in-office visit. In-office visits also have more benefits. Here is a quote from the report that is debatable at best “over the next few years, telehealth will remain the domain of the younger digital natives.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 15, 2022
Francis Crick Institute and King’s College London collaborate to identify specialist cells which protect DNA
Bio Pharma Dive
FEBRUARY 16, 2022
Study results indicate the company's fast-acting medicine may help patients already on existing drugs. But its limited effects may curb its potential, Wall Street analysts said.
World of DTC Marketing
FEBRUARY 15, 2022
Biotech startups are hurting for money as investments in biotech startups start to decline. Biotechs need to think like marketers to cut through the noise and attract investors. It begins with a CEO who not only has a stellar medical background but understands how to get the company on the radar. There are so many biotech startups right now that there isn’t enough money for them all to continue the development of new drugs.
pharmaphorum
FEBRUARY 14, 2022
Moderna is reportedly in late-stage negotiations with the UK government that could result in a new research and manufacturing facility being set up in the biotech ‘golden triangle’ between London, Oxford and Cambridge. The development has been prompted by a desire on the behalf of the US biotech to collaborate with the NHS, according to a report in the Financial Times, which cites people familiar with the matter.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
FEBRUARY 18, 2022
New combination treatment can significantly reduce the risk of death among prostate cancer patients
Bio Pharma Dive
FEBRUARY 14, 2022
At an industry conference Monday, a group of venture investors noted changes in how long biotechs are taking to raise money, and a shifting outlook among investors who specialize in shepherding young companies to an IPO.
World of DTC Marketing
FEBRUARY 16, 2022
COVID may be winding down, but the damage is done in deaths and long COVID. We don’t understand much, but we do know that there is a correlation between COVID severity and obesity/diabetes. The question thus becomes, “will the medical community finally address the obesity epidemic, or will we continue to do nothing essentially?” Obesity turned out to be a significant risk factor for covid hospitalization and death, especially non-elderly.
pharmaphorum
FEBRUARY 15, 2022
One in four of the world’s rivers are polluted with potentially toxic levels of pharma compounds, according to a new study. The findings point to a “threat to environmental and global health,” say the scientists, who found that paracetamol, antibiotics epilepsy drug carbamazepine, metformin for diabetes and other compounds like caffeine and nicotine were found in samples from around the world – including in Antarctica.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
JAMA Internal Medicine
FEBRUARY 17, 2022
This randomized clinical trial assesses the efficacy of ivermectin treatment in preventing progression to severe disease among high-risk patients with COVID-19 in Malaysia.
Bio Pharma Dive
FEBRUARY 15, 2022
Early study results suggest some efficacy for Amgen's KRAS-targeting drug in the tough-to-treat cancer type. The biotech plans to expand testing as a result.
XTalks
FEBRUARY 18, 2022
Dig Restaurant Group, a chain of locally farm sourced restaurants, is taking a page from the corporate world and introducing four-day workweeks to the quick service restaurant (QSR) industry. While salaried office workers tend to be the most popular cohort trialing the four-day workweek, hourly workers at some of Dig’s locations will be getting the same perk.
pharmaphorum
FEBRUARY 18, 2022
Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don’t respond to the only approved biologic treatment, Novartis/Roche’s Xolair. . CSU is a severe form of hives that affects around 1% of the global population, causing severe itching and swelling that can last for weeks at a time and resist even very high doses of antihistamines, the standard, first-line therapy for the condition.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fossil Remedies
FEBRUARY 18, 2022
PCD Pharma Franchise Business. Why are more aspirants willing to make a career in the field of pharmaceuticals? It is because the business is not only promising, but it is going to remain profitable for many years. People have become health conscious and they want to maintain fitness. Also, the recent Covid-19 outbreak has also changed the scenario.
Bio Pharma Dive
FEBRUARY 16, 2022
Natalie Holles was named as head of the Atlas-backed startup last year after leaving gene therapy developer Audentes following its acquisition by Astellas.
BioPharma Reporter
FEBRUARY 16, 2022
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
Intouch Solutions
FEBRUARY 15, 2022
Each year, we ask Intouch creatives to share their thoughts on the latest Super Bowl ads. This year, for Super Bowl LVI, we’re back with more creatives and more reactions. But wait: When you get a bunch of creatives (and one strategic planner) “in a room together,” can you get quick consensus? Turns out yes. Pretty much everyone agreed that the audience in mind was Gen X; that celebrities were more rampant than ever; and Eugene Levy driving fast with Fabio hair is AWESOME.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
FEBRUARY 13, 2022
German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process. Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity.
Bio Pharma Dive
FEBRUARY 14, 2022
The European regulator began a safety review of so-called Janus kinase inhibitors from Pfizer, AbbVie, Eli Lilly and Galapagos, citing worrisome data from a study of Pfizer's drug Xeljanz.
XTalks
FEBRUARY 14, 2022
Valentine’s Day is a celebration of love, and to many, that entails food. From heart-shaped treats to to buy one, get one free (BOGO) deals to share with loved ones, restaurants nationwide are celebrating the holiday in a delicious way. Here are some of this year’s Valentine’s Day food offers from choice-favorite restaurants and fast-food chains, starting with the savory, then the sweet. .
Scienmag
FEBRUARY 14, 2022
Algae are more than just the green scum that shows up on aquarium walls. The tiny plants, when teamed up with a fungus, can form a composite structure called lichen. Lichens grow everywhere, from tundras in the Arctic to the bark of the tree in your yard, and they do everything from creating oxygen to […].
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
FEBRUARY 18, 2022
Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England Journal of Medicine.
Bio Pharma Dive
FEBRUARY 15, 2022
By partnering with ONK Therapeutics, Intellia joins CRISPR Therapeutics and Editas Medicine in striking deals that marry gene editing with a fast-emerging form of cancer immunotherapy.
Outsourcing Pharma
FEBRUARY 15, 2022
An expert from the institutional review board services company advises what trends to look for in the clinical trial industry over the course of coming months.
XTalks
FEBRUARY 16, 2022
The globalization of the food chain has resulted in increased complexity and digital activity, meaning more opportunities for food fraud to occur. Since the COVID-19 pandemic forced many grocery stores, quick-service restaurants (QSRs) and other food industry players to pivot to digital technologies including mobile apps and contactless payment methods, food fraud has been prevalent in recent years.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
341 
Let's personalize your content